neuren dec21 Ann. and future dimeric march 2024 Ann. aren't equivalent.
neuren dec 21 was their final phase 3 result.
dimerix March 2024 1st interim analysis is a FUTILITY analysis on 35 week urine protein result in 72 patients in their fgfs trial, that's what their abstract for the American nephrology congress says (anybody can download it).
as with any futility analysis, If standard practice is followed in this trial then it's a binary outcome (pass/fail) come march...
either: trial doesn't meet a predefined futility level on the urine protein result in the 72 patients, trial could be stopped as it's "futile" to keep going. or
trial does pass that minimum level, then expect a report on how comfortably it passed, and what are chances of achieving urine protein endpoint at the study end. That's how a futility interim is normally run and communicated in my experience.
But as I understand it GFR isn't part of that first interim analysis according to their release, and that's the main endpoint of the trial after about 2 years.
different to neuren as I said at start.
- Forums
- ASX - By Stock
- DXB
- Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma, page-129
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
57.5¢ |
Change
0.020(3.60%) |
Mkt cap ! $318.8M |
Open | High | Low | Value | Volume |
57.0¢ | 59.5¢ | 56.5¢ | $810.0K | 1.397M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 222079 | 57.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
57.5¢ | 6214 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 12066 | 0.575 |
5 | 248629 | 0.570 |
5 | 55644 | 0.565 |
14 | 440486 | 0.560 |
5 | 89332 | 0.555 |
Price($) | Vol. | No. |
---|---|---|
0.580 | 38357 | 3 |
0.585 | 14729 | 3 |
0.590 | 34477 | 4 |
0.595 | 54619 | 4 |
0.600 | 57450 | 5 |
Last trade - 11.43am 20/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online